Phase II study shows HRPC patients with bone metastases see improved survival w... ( Macclesfield UK 25 September 2007. N...)

Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054

Date:9/25/2007

Macclesfield, UK, 25 September 2007. New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo (HR 0.55; 80 percent CI 0.41, 0.73).1

To further evaluate ZD4054s potential, the Phase III trial programme ENTHUSE (ENDOTHELIN A USE), consisting of three studies, will begin this year. The first of these trials is aimed at investigating the efficacy of ZD4054 in metastatic HRPC, while the second will look at its role in non-metastatic HRPC patients. A third trial will study ZD4054 in combination with docetaxel (TaxotereTM) for the treatment of metastatic HRPC.

The results from the randomised, double-blind, placebo-controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist - were delivered today at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).

Nick James, Professor of Clinical Oncology, Institute for Cancer Studies, Birmingham, UK, and principal investigator of the EPOC study said: Men with advanced prostate cancer are typically treated with hormonal therapies. Whilst these therapies can provide great benefits, most men will become resistant to them. Currently, the only licensed treatment option for metastatic patients shown to improve survival in men with HRPC is chemotherapy with docetaxel.

The promising results from the EPOC study suggest that ZD4054 10mg once-daily has the potential to increase the median overall survival time for men with asymptomatic or mildly symptomatic metastatic HRPC, with the benefit of a manageable side-effect profile and the convenience of on
'/>"/>

Contact: Aoife Gallagher
aoife_gallagher@uk.cohnwolfe.com
44-078-943-86422
Cohn & Wolfe Healthcare, London
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. SARS-Free Taiwan to Mark End Phase of Global Fight
3. S. Africa AIDS in death phase
4. Spray on contraceptive clears Phase I trial
5. Phase 3 trials of two multi-kinase inhibitors against cancer
6. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
7. Phase II trails of new HIV vaccine to be held in South Africa
8. Phase 1 Drug Trials on Humans to Be Made Public
9. Jalgaon: Third Phase Of Culling Operations Begin
10. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
11. Cadila to Commence Phase I Clinical Trials On ZYH2

Post Your Comments:

(Date:12/1/2009)... A new mind-body medicine study conducted by Th...aily meditation, diaphragmatic breathing and yoga ...physical, mental and emotional health benefits. ,...December 1, 2009 –– A new retrospectiv...on and yoga practices learned by students who atte...

(Date:12/1/2009)... The Daniel Jordan Fiddle Foundation, a nationa... advocate for, and support programs and services f...orders (ASD), has released a free informational br...res: How To Recognize The Signs and Basic First A...ew York, NY (PRWEB) December 1, 2009 -- Statistics...

(Date:12/1/2009)...BEACH, Calif., Dec. 1 To date, hos... will reimburse them for the $20 cost of the dispo...er, for surgery. ,, Anesthesiologists have not ...o avoid postop dementia from routine anesthesia ov...ard the ,avoid over-medication, message from their...

(Date:12/1/2009)... Dec. 1 What many spa clients have...d journalists has proclaimed in the 2009 AsiaSpa A..., Taking five citations including "Asian Spa Capi...ers in the fifth AsiaSpa Awards, presented by Asia... wellness publication, during a glittering ceremon...

(Date:12/1/2009)... SHENZHEN, China, Dec. 1 /PRNewswire-Asia-Firs...: NPD ) ("Nepstar" or "the Company"), the larges...ber of directly operated stores,today announced i...er ended,September 30, 2009. ,, Financial...rminated a voting rights assignment agreement,whi...

[0] New American Meditation Institute Study Reports Wide-Ranging Health Benefits from Meditation and Yoga [0] Daniel Jordan Fiddle Foundation for Adults with Autism Offers Free Epilepsy First-Aid Brochure [0] 5 Shocking Reasons Your Brain Isn't Worth Twenty Bucks Exposed [0] Thailand - Spa Capital of Asia by Karen Emmons [0] China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009

...oratec Corporation (Nasdaq: THOR ), a world lead...therapies to save, support and restore failing hea...ting results for the first quarter of fiscal 2009 ...ies at 1:30 p.m., Pacific Daylight Time (4:30 p.m....

...re Mexican companies doing about the threats of Sw...Mexican food and non-alcoholic beverages imported ...,000 points of distribution know that your product...s, and individual stores, that Novamex was concern...

...e-USNewswire/ -- Alzheimer,s disease is gaining ...5.3 million Americans living with the disease. Pr...ome, people living with Alzheimer,s -- along with ...t shows there is now genuine reason to be optimis...

...calcium channel blocker, angiotensin receptor bloc...rothiazide) in one pill , , - In a clinical tria...reductions in systolic and diastolic BP, compared ...eed three or more , , - Exforge HCT can help app...

...irstCall/ - IMRIS Inc. (TSX: IM) ("IMRIS" or the "... integrated MR imaging and x-ray angiography suite...esolve and confirm the effectiveness of treatment ...and advanced neurovascular interventions and IMRIS...

...e Samaritan Pacific Hospital Foundation,s response...nnual spring fashion show fundraiser, West Coast B...nch Manager-Vice President Julie Hanrahan, also a ... Stroll Fashion Show to benefit the Pacific Commu...

Other Medicine News:Health News:Thoratec Schedules First Quarter Conference Call, Webcast 2 Health News:The Alzheimer's Project HBO Documentary Puts Spotlight on Alzheimer's Disease; North Dakota Family Featured 2 Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 2 Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 3 Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 4 Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 5 Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 6 Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 7 Health News:IMRIS receives CE Mark approval for interventional imaging system 2 Health News:West Coast Bank's Employees Organize A Paris Stroll Fashion Show to Benefit Women's Cancer Fund 2

Thoratec Schedules First Quarter Conference Call, Webcast Imported Mexican Food and Beverages Safe for Consumers The Alzheimer's Project HBO Documentary Puts Spotlight on Alzheimer's Disease; North Dakota Family Featured Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill IMRIS receives CE Mark approval for interventional imaging system West Coast Bank's Employees Organize A Paris Stroll Fashion Show to Benefit Women's Cancer Fund

(Date:12/1/2009)... , BOSTON, Dec. 1 /PRNewswire-FirstC...ration (Nasdaq: PRXL ), a leading global biopharm...cussion on innovative approaches to drug developme...Asia Pacific Conference, being held December 1-3, ...AREXEL is a sponsor of the conference, which is fo...

(Date:11/30/2009)... , MINNEAPOLIS, Nov. 30 N...ogical monitoring solutions and the inventor of fi...ivan,s 2009 North American Product Line Strategy A...providing secure, accurate remote physiological mo...eadership as a premier provider of telemedicine mo...

(Date:11/30/2009)... , CLEVELAND, Nov. 30 /PRNewswire-FirstCall/...technology and services company focused on global ...ry, today announced that PFC Pharma Focus AG (PFC)...have the ability to contract for DATATRAK,s CRO pa...eClinical(TM) product suite. In addition, PFC wil...

Breaking Medicine Technology:PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 2 PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 3 PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 4 Nonin Medical is Recognized by Frost & Sullivan for Remote Patient Monitoring Leadership 2 Nonin Medical is Recognized by Frost & Sullivan for Remote Patient Monitoring Leadership 3 PFC Pharma Joins DATATRAK's CRO Connect Program 2 PFC Pharma Joins DATATRAK's CRO Connect Program 3 PFC Pharma Joins DATATRAK's CRO Connect Program 4 New old drug fights colon cancer 59359 1 New old drug fights colon cancer 59359 2 A new scan for lung diseases 59354 1 A new scan for lung diseases 59354 2 Magnetic nanotags spot cancer in mice earlier than methods now in clinical use 10332 1 Magnetic nanotags spot cancer in mice earlier than methods now in clinical use 10332 2 Magnetic nanotags spot cancer in mice earlier than methods now in clinical use 10332 3 Magnetic nanotags spot cancer in mice earlier than methods now in clinical use 10332 4 Magnetic nanotags spot cancer in mice earlier than methods now in clinical use 10332 5

[0] PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference [0] Nonin Medical is Recognized by Frost & Sullivan for Remote Patient Monitoring Leadership [0] PFC Pharma Joins DATATRAK's CRO Connect Program

...Pharmaceuticals, Inc., a,clinical-stage biopharmac...ing novel RNA interference-based therapeutics, ann...pointed as the Company,s new Chief Medical,Officer... in supporting Quark,s,current clinical programs a...,s pipeline. Prior to joining Quark, Dr. Marr ser...

...ndary Endpoints, San Carlos, Calif., Sept. 4 Neu... company focused on developing novel,pain manageme...sults from,its second pivotal study of NGX-4010, t...nist -- synthetic capsaicin -- in patients with po...ter, double-blind, controlled Phase,3 trial, met i...

Other Medicine Technology:Quark Pharmaceuticals Appoints New Chief Medical Officer 2 Quark Pharmaceuticals Appoints New Chief Medical Officer 3 Quark Pharmaceuticals Appoints New Chief Medical Officer 4 NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 2 NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 3 NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 4 NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 5 NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 6 NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 7

Quark Pharmaceuticals Appoints New Chief Medical Officer NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia

Rubeola Measles

Anti-Measles IgG Assay

Captia Measles IgM (2 plate)

...Immunosorbent Assays(ELISA) is intended for the de...body to Measles Rubeola) virus in human sera. Indi...nation of immune status. Paired sera, acute and,...rsion or a significant rise in antibody as an aid ...

Medicine Products:

Rubeola Measles Anti-Measles IgG Assay Captia Measles IgM (2 plate)Captia Measles IgG (5)

Phase II study shows HRPC patients with bone metastases see improved survival w...( Macclesfield UK 25 September 2007. N...),Health